Clinical Trials Logo

Healthy Men clinical trials

View clinical trials related to Healthy Men.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05968508 Active, not recruiting - Healthy Men Clinical Trials

A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects

Start date: August 29, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, single-dose, two-arm parallel study to compare the pharmacokinetics, safety and immunogenicity of BAT1806 prefilled subcutaneous injection with RoActemra® (from EU) in healthy male subjects.

NCT ID: NCT05825781 Active, not recruiting - Healthy Men Clinical Trials

Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

Start date: July 20, 2023
Phase: Phase 1
Study type: Interventional

PERT-1/12102020 is a double-blind randomized single-center clinical trial comparing pharmacokinetics, immunogenicity and safety profiles of Pertuzumab (manufactured by Mabscale, LLC) compared to Perjeta® in healthy men. The purpose of the study is to demonstrate equivalence of pharmacokinetics, immunogenicity and safety of Pertuzumab (manufactured by Mabscale, LLC) to Perjeta®.

NCT ID: NCT03298373 Active, not recruiting - Healthy Men Clinical Trials

28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

CCN014A
Start date: November 9, 2017
Phase: Phase 1
Study type: Interventional

This is a Phase I multicenter, double-blind, repeat dose, dose-escalating study, in healthy men to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC).

NCT ID: NCT02754687 Active, not recruiting - Healthy Men Clinical Trials

Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

CCN014
Start date: April 2016
Phase: Phase 1
Study type: Interventional

The long term objective is to develop a new male hormone 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) as a male hormonal contraceptive.